Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

As researchers continue to advance the understanding of Alzheimer’s disease, new treatment options are offering hope for ...

Modified Kisunla dosing cut ARIA-E risk by 41% at 24 weeks and 35% at 52 weeks. Amyloid plaque reduction remained similar: 67% (modified) vs. 69% (original) at 24 weeks. Get a Year of Fast, Actionable ...

INDIANAPOLIS — A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines ...

Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the ...

Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024 "Bringing Alzheimer's disease treatment options to the ...

You might recall how, earlier this year, people started talking about how something might be “seriously wrong” with the ...

INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the ...